Back Indapamied Afrikaans إنداباميد Arabic اینداپامید AZB Indapamid Welsh Indapamid German Indapamide French Indapamid Croatian Indapamid Hungarian Ինդապամիդ Armenian Indapamide Italian
 | |
| Clinical data | |
|---|---|
| Trade names | Lozol, Natrilix |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a684062 |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 71–79% |
| Metabolism | Liver |
| Elimination half-life | standard release: 14–18 hours,[2] slow release: 14–24 hours (mean 18)[3] |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.043.633 |
| Chemical and physical data | |
| Formula | C16H16ClN3O3S |
| Molar mass | 365.83 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Indapamide is a thiazide-like diuretic[4] drug used in the treatment of hypertension, as well as decompensated heart failure. Combination preparations with perindopril (an ACE inhibitor antihypertensive) are available. The thiazide-like diuretics (indapamide and chlorthalidone) reduce risk of major cardiovascular events and heart failure in hypertensive patients compared with hydrochlorothiazide with a comparable incidence of adverse events.[5] Both thiazide diuretics and thiazide-like diuretics are effective in reducing risk of stroke.[5][6][7] Both drug classes appear to have comparable rates of adverse effects as other antihypertensives such as angiotensin II receptor blockers and dihydropyridine calcium channel blockers and lesser prevalence of side-effects when compared to ACE-inhibitors and non-dihydropyridine calcium channel blockers.[5][8]
It was patented in 1968 and approved for medical use in 1977.[9] It is on the World Health Organization's List of Essential Medicines.[10]
- ^ "Active substance(s): indapamide" (PDF). List of nationally authorised medicinal products. Human Medicines Evaluation Division, European Medicines Agency. 22 July 2021.[permanent dead link]
- ^ "Indapamide 2.5mg Tablets - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 2024-06-03.
- ^ "Natrilix SR 1.5 mg Tablets - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 2024-06-03.
- ^ Indapamide at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- ^ a b c Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ (May 2015). "Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis". Hypertension. 65 (5): 1033–1040. doi:10.1161/HYPERTENSIONAHA.114.05122. PMID 25733241.
- ^ "Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party". BMJ. 304 (6824): 405–412. February 1992. doi:10.1136/bmj.304.6824.405. PMC 1995577. PMID 1445513.
- ^ Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. (May 2008). "Treatment of hypertension in patients 80 years of age or older". The New England Journal of Medicine. 358 (18): 1887–1898. doi:10.1056/NEJMoa0801369. PMID 18378519.
- ^ Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. (November 2019). "Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis". Lancet. 394 (10211): 1816–1826. doi:10.1016/s0140-6736(19)32317-7. PMC 6924620. PMID 31668726.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 457. ISBN 9783527607495.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.